<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04057391</url>
  </required_header>
  <id_info>
    <org_study_id>QT MG PRE Phase 1</org_study_id>
    <nct_id>NCT04057391</nct_id>
  </id_info>
  <brief_title>Understanding Patient Experience and Preferences for the QT Scanner Compared to Mammography</brief_title>
  <official_title>Understanding Patient Experience and Preferences for the QT Scanner Compared to Mammography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QT Ultrasound LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Analysis Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>QT Ultrasound LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to characterize patient experience, satisfaction and preference for use of
      the QT Scanner in comparison to mammography by directly engaging women who have experience
      with both technologies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives will be addressed by first conducting structured one-on-one interviews with
      about 20 women (Qualitative Phase), and then administering a web-based patient survey with
      quantitative measurements in about 200 women (Quantitative Phase). The current Protocol
      registration pertains to the first, qualitative phase of the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 6, 2019</start_date>
  <completion_date type="Anticipated">October 18, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Qualitative phase: structured one-on-one interviews</measure>
    <time_frame>30 days</time_frame>
    <description>one-on-one interviews will be conducted by trained professionals with about 20 women</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer Screening</condition>
  <arm_group>
    <arm_group_label>QT Scanner in comparison to mammography</arm_group_label>
    <description>Women who have experience with both technologies (QT Scanner/Breast mammography</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>QT Scanner</intervention_name>
    <description>Diagnostic test that is repeatable, non-invasive imaging tool for the early and accurate detection of breast cancer, breast abnormalities, and musculoskeletal findings. Comparing with mammography, the QT Scanner uses harmless soundwaves to screen and diagnose the breast.</description>
    <arm_group_label>QT Scanner in comparison to mammography</arm_group_label>
    <other_name>Quantitative Transmission Ultrasound Breast Scanner-1</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study target population are women who have experience with both the QT Scanner and
        mammography.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have used the QT Scanner

          -  Have used mammography

          -  Speak English

          -  Willing to provide consent and participate in the survey

        Exclusion Criteria:

        â€¢ Excluded if all Inclusion Criteria are not met
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Analysis Group, Inc.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://seer.cancer.gov/statfacts/html/breast.html</url>
    <description>National Cancer Institute S, Epidemiology, and End Results Program,. Cancer Stat Facts: Female Breast Cancer.</description>
  </link>
  <link>
    <url>https://www.nationalbreastcancer.org/breast-cancer-facts</url>
    <description>National Breast Cancer Foundation I. Facts about breast cancer in the United States. 2019</description>
  </link>
  <link>
    <url>https://www.cancer.org/content/cancer/en/research/infographics-gallery/breast-cancer-screening-guideline.html</url>
    <description>Amercian Cancer Society. Breast Cancer Screening Guideline.</description>
  </link>
  <link>
    <url>https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf</url>
    <description>American Cancer Society. Breast Cancer Facts &amp; Figures 2017-2018.</description>
  </link>
  <reference>
    <citation>Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, Rothman M; PRO Harmonization Group. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health. 2003 Sep-Oct;6(5):522-31.</citation>
    <PMID>14627058</PMID>
  </reference>
  <reference>
    <citation>Blumen H, Fitch K, Polkus V. Comparison of Treatment Costs for Breast Cancer, by Tumor Stage and Type of Service. Am Health Drug Benefits. 2016 Feb;9(1):23-32.</citation>
    <PMID>27066193</PMID>
  </reference>
  <reference>
    <citation>Johnson FR, Zhou M. Patient Preferences in Regulatory Benefit-Risk Assessments: A US Perspective. Value Health. 2016 Sep - Oct;19(6):741-745. doi: 10.1016/j.jval.2016.04.008.</citation>
    <PMID>27712700</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

